Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression
Authors:
- M PuhlmannMPM Puhlmann
- J LeeJLJ Lee
- Y HuYHY Hu
- Sk LibuttiSLSk Libutti
- Hr AlexanderHAHr Alexander
- Dl BartlettDBDl Bartlett
- 1 July 2000
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (14) , 1217-1223
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 27 references indexed in Scilit:
- Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207Human Gene Therapy, 1999
- Augmentation of Melanoma-Specific Gene Expression Using a Tandem Melanocyte-Specific Enhancer Results in Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene in MelanomaHuman Gene Therapy, 1999
- Thymidine Kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vector for Tumor-Directed Gene TherapyHuman Gene Therapy, 1999
- Killing tumor cells with viruses—a question of specificityNature Medicine, 1998
- An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapyNature Biotechnology, 1998
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996
- Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.Proceedings of the National Academy of Sciences, 1996
- Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus MutantScience, 1991
- Structure of vaccinia virus late promotersJournal of Molecular Biology, 1989
- Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotypeNature, 1985